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Antimalarial and antitubercular agents with new mechanisms of action are necessary to 
tackle Plasmodium parasites and Mycobacteria resistant to all current therapies. 
Fosmidomycin has been shown to be a well-tolerated, safe and efficacious antimalarial drug 
in combination treatment. However, its pharmacokinetic properties are less than ideal, with 
only moderate bioavailability and a short plasma half-life. Moreover, because of the unique 
highly lipophilic cell wall of Mycobacteria, fosmidomycin cannot cross the cell wall and thus, 
is not active against Mycobacteria. 
 
A lot of research has been done on the design of highly active fosmidomycin analogs. 
However, the problem of low bioavailability remains. Conversion into hydrophobic 
phosphonate prodrugs can improve both oral bioavailability and cell penetration by passive 
diffusion. To date, only acyloxymethyl- and alkoxycarbonyloxymethyl prodrugs have been 
reported in the literature. The aim of this project is to synthesize a broad range of prodrugs 
of fosmidomycin analogs and to test them for whole cell activity against Plasmodium species 
and Mycobacteria. 
 
In this poster, we will present the synthesis of HepDirect and alkoxyalkyl phosphonate 
esters. A short and broadly applicable synthesis route was designed, the key step being 
cross metathesis. We will also present our ongoing efforts towards the synthesis of 
phosphonamidate prodrugs. 
 
 
